Telix Pharmaceuticals has submitted regulatory applications for TLX101-Px, a brain cancer imaging agent, to both the European Medicines Agency and the U.S. Food and Drug Administration, seeking approval for glioma diagnosis and treatment monitoring.
Telix Pharmaceuticals submitted a marketing authorization application in Europe for TLX101-Px, a glioma imaging agent, on February 18, 2026. The filing covers major European markets and a U.S. NDA submission will follow.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07416188 |
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma |
RECRUITING | PHASE1/PHASE2 |
| NCT06742593 |
Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors |
NOT_YET_RECRUITING | PHASE1 |
| NCT03965494 |
AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery |
TERMINATED | EARLY_PHASE1 |
| NCT03696355 |
Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas |
COMPLETED | PHASE1 |
| NCT03150862 |
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma |
COMPLETED | PHASE1/PHASE2 |
| NCT01585389 |
Studying Gene Expression and Location in Samples From Patients With Brain Tumors |
COMPLETED | |
| NCT01553175 |
Studying Gene Expression in Samples From Patients With Rhabdoid Tumors |
COMPLETED | |
| NCT01480050 |
Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma |
COMPLETED | PHASE1 |
| NCT01390571 |
Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma |
COMPLETED | PHASE1 |
| NCT01381718 |
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor |
COMPLETED | PHASE2 |
